12:00 AM
Oct 07, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

AC105: Phase II started

Acorda began a double-blind, placebo-controlled Phase II trial to evaluate 6 doses of IV AC105 over 30 hours in about 40 patients with traumatic SCI. Acorda received a $2.7 million...

Read the full 127 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >